Enhanced skin delivery of aceclofenac via hydrogel-based solid lipid nanoparticles
Source abstract
Abstract
The aim of the present study was to develop solid lipid nanoparticles (SLN) and formulate a hydrogel for enhanced topical delivery of aceclofenac (ACF). The SLN were prepared by the ultrasonic emulsification method and optimized on the basis of stirring speed and lipid content. The optimized formulation was characterized for particle size (189 ± 9.2 nm), polydispersity index (PDI) (0.162 ± 0.02), zeta potential (-32.51 ± 0.12 mV), entrapment efficiency (86.51 ± 2.46%), surface morphology, differential scanning calorimetry (DSC) and X-ray diffraction (XRD). In vivo performance of ACF-loaded SLN hydrogel showed prolonged inhibition of edema, as compared to that observed using plain ACF hydrogel, after 24 h. The results demonstrated that the ACF-SLN formulation for skin targeting could be a promising carrier for topical delivery of ACF.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Dermatology and Skin Diseases · Essential Oils and Antimicrobial Activity
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidayalaya, Bilaspur, India
Department of Pharmaceutical Science, Dr. Hari Singh Gour University Sagar, Madhya Pradesh, India
References (32)
Show source-provided references
1. 10.1016/j.ejpb.2004.03.02710.1016/j.ejpb.2004.03.027 ↗
2. 10.1155/2008/90378410.1155/2008/903784 ↗
3. 10.1016/0378-5173(95)04286-510.1016/0378-5173(95)04286-5 ↗
4. 10.1016/j.ijpharm.2005.08.01110.1016/j.ijpharm.2005.08.011 ↗
5. 10.2478/v10007-010-0026-710.2478/v10007-010-0026-7 ↗
6. 10.1016/j.colsurfb.2011.12.00610.1016/j.colsurfb.2011.12.006 ↗
7. 10.1016/j.jconrel.2005.09.05210.1016/j.jconrel.2005.09.052 ↗
8. 10.1002/jps.260084041510.1002/jps.2600840415 ↗
9. 10.2478/v1007-010-0036-510.2478/v1007-010-0036-5 ↗
10. 10.1016/j.biomaterials.2006.01.06010.1016/j.biomaterials.2006.01.060 ↗
11. 10.1016/S0142-9612(02)00578-110.1016/S0142-9612(02)00578-1 ↗
12. 10.1021/js960040u10.1021/js960040u ↗
13. 10.1080/0265204001000036110.1080/02652040010000361 ↗
14. 10.1016/S0939-6411(99)00075-210.1016/S0939-6411(99)00075-2 ↗
15. 10.1016/j.ijpharm.2006.08.00710.1016/j.ijpharm.2006.08.007 ↗
16. 10.1007/s11095-006-0143-710.1007/s11095-006-0143-7 ↗
17. 10.1016/j.jconrel.2006.05.01010.1016/j.jconrel.2006.05.010 ↗
18. 10.1016/S0378-5173(99)00413-510.1016/S0378-5173(99)00413-5 ↗
19. 10.1081/DDC-20004779110.1081/DDC-200047791 ↗
20. Muller RH · Eur J Pharm Biopharm · 1995 · 41 · 62
21. 10.1016/S0169-409X(02)00118-710.1016/S0169-409X(02)00118-7 ↗
22. Musmade P · Analytica Chem Acta · 2007 · 585 · 1082
23. 10.1016/j.jpain.2010.10.01310.1016/j.jpain.2010.10.013 ↗
24. 10.1002/jps.2274110.1002/jps.22741 ↗
25. Rowe RC · 2002 · 264
26. 10.1046/j.1365-2133.1998.02166.x10.1046/j.1365-2133.1998.02166.x ↗
27. 10.1016/j.ijpharm.2007.05.06110.1016/j.ijpharm.2007.05.061 ↗
28. 10.1208/pt080410410.1208/pt0804104 ↗
29. 10.1016/j.ijpharm.2004.02.03210.1016/j.ijpharm.2004.02.032 ↗
30. 10.1016/j.ejpb.2004.02.01510.1016/j.ejpb.2004.02.015 ↗
31. Winter CA · Nonsteroidal Anti-inflmmat Drug · 1965 · 52 · 190
32. 10.1016/S0168-3659(02)00056-110.1016/S0168-3659(02)00056-1 ↗